Ngm Biopharmaceuticals

Ngm Biopharmaceuticals company information, Employees & Contact Information

NGM Bio is a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. In addition to a healthy balance sheet and cash runway, the company currently has four programs in active clinical development. Visit us at www.ngmbio.com for more information.

Company Details

Employees
108
Founded
-
Address
333 Oyster Point Blvd., South San Francisco,ca 94080,united States
Phone
6505831646
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
ngmbio.com
Keywords
Engineer jobs.
HQ
South San Francisco, CA
Looking for a particular Ngm Biopharmaceuticals employee's phone or email?

Ngm Biopharmaceuticals Questions

News

NGM Bio slims down in strategic pivot, cutting 75% of staff and halting a midstage liver disease program - Fierce Biotech

NGM Bio slims down in strategic pivot, cutting 75% of staff and halting a midstage liver disease program Fierce Biotech

NGM Bio Announces First Participant Dosed in EMERALD Phase - GlobeNewswire

NGM Bio Announces First Participant Dosed in EMERALD Phase GlobeNewswire

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer - GlobeNewswire

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer GlobeNewswire

NGM Bio Announces Closing of Tender Offer - Yahoo Finance

NGM Bio Announces Closing of Tender Offer Yahoo Finance

NGM Bio and KdT Ventures Enter into Worldwide License - GlobeNewswire

NGM Bio and KdT Ventures Enter into Worldwide License GlobeNewswire

NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer - PR Newswire

NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer PR Newswire

Newly Private NGM Bio Raises $122M for Registrational PSC Study - BioSpace

Newly Private NGM Bio Raises $122M for Registrational PSC Study BioSpace

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum - Yahoo Finance

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum Yahoo Finance

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial The Lancet

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis - MarketBeat

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis MarketBeat

NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD) - PR Newswire

NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD) PR Newswire

NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting - Yahoo Finance

NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting Yahoo Finance

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP - GlobeNewswire

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP GlobeNewswire

NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH - PR Newswire

NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH PR Newswire

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities - GlobeNewswire

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities GlobeNewswire

NGM Bio Announces New Clinical Data from Ongoing Trial of - GlobeNewswire

NGM Bio Announces New Clinical Data from Ongoing Trial of GlobeNewswire

Top Ngm Biopharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant